<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868568</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-1959</org_study_id>
    <secondary_id>2007-006110-42</secondary_id>
    <nct_id>NCT01868568</nct_id>
  </id_info>
  <brief_title>Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Randomised, Double-blind, Multiple Period Cross-over Trial Comparing Insulin 454 and Insulin Aspart Fixed Combination Products With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared to Biphasic Insulin Aspart 30 (NovoMix® 30) in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and
      insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of
      insulin degludec (insulin 454) and insulin aspart, compared with biphasic insulin aspart 30
      (NovoMix® 30) in subjects with type 1 diabetes mellitus. Each subject will be randomised to
      four out of nine possible treatment arms. IDegAsp 40, IDegAsp 45, IDegAsp 55 and IDeg high
      concentration were explorative formulations, not similar to the proposed commercial
      formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin aspart concentration curve</measure>
    <time_frame>0-2 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate curve</measure>
    <time_frame>0-26 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin 454 concentration curve</measure>
    <time_frame>0-120 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>IDegAsp 30 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart + insulin degludec - low concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDegAsp 40 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDegAsp 45 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart + insulin degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDegAsp 55 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 30 + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>Insulin aspart + insulin degludec - low concentration 1</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration 1</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart 30</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp 30 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart 40</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp 40 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart 45</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp 45 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart 55</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp 55 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>Insulin aspart + insulin degludec - low concentration 1</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration 1</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec</arm_group_label>
    <arm_group_label>Insulin aspart + insulin degludec - high concentration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>BIAsp 30 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>IDegAsp 30 + placebo</arm_group_label>
    <arm_group_label>IDegAsp 40 + placebo</arm_group_label>
    <arm_group_label>IDegAsp 45 + placebo</arm_group_label>
    <arm_group_label>IDegAsp 55 + placebo</arm_group_label>
    <arm_group_label>BIAsp 30 + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glycosylated haemoglobin A1c (HbA1c) below or equal to 10.0 % based on central
             laboratory results

          -  Diagnosed with type 1 diabetes and treated with insulin for above or equal to 12
             months

          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  A subject with a history of significant multiple drug allergies or with a known or
             suspected allergy to the trial product or any medicine chemically related to the
             trialproduct, as judged by the Investigator

          -  A subject who is known to have hepatitis or who is carrier of the Hepatitis B surface
             antibodies, or has a positive result to the test for HIV antigen (HBsAg) or Hepatitis
             C antibodies

          -  A subject who has participated in any other trials involving investigational products
             within the 3 months preceding the start of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

